Table 3.
Clinical Characteristics of NRF2 Protein Expression Groups (181 Patients)
| N (%) (181) (100) | High Expression 54 (29.83) | Low Expression 127 (70.17) | P |
|---|---|---|---|
| Gender (M/F) | 45/9 | 114/13 | 0.226 |
| HBsAg (±) | 44/10 | 108/19 | 0.550 |
| Cirrhosis (±) | 47/7 | 105/22 | 0.464 |
| MVI (±) | 25/29 | 53/74 | 0.571 |
| BCLC (0+A/B+C) | 24/30 | 65/62 | 0.407 |
| Tumor differentiation (I+II/III+IV) | 32/22 | 81/46 | 0.566 |
| AFP (Normal/ Elevated) | 14/40 | 52/75 | 0.055 |
| CEA (Normal/ Elevated) | 49/5 | 118/9 | 0.844 |
| CA19-9 (Normal/ Elevated) | 46/8 | 93/34 | 0.081 |
| Number of lesions (single/multiple) | 43/11 | 108/19 | 0.371 |
| Tumor size (≤5/>5) | 33/21 | 54/73 | 0.022 |
| Encapsulation (yes/no) | 27/27 | 73/54 | 0.354 |
| Tumor thrombus *(180) (yes/no) | 7/47 | 20/106 | 0.616 |
| ALT (Normal/Elevated) | 28/26 | 77/50 | 0.274 |
| AST * (168) (Normal/ Elevated) | 30/20 | 80/38 | 0.331 |
| ALP * (164) (Normal/ Elevated) | 44/4 | 100/16 | 0.331 |
| GGT * (164) (Normal/ Elevated) | 14/34 | 39/77 | 0.579 |
| TB * (174) (Normal/ Elevated) | 48/3 | 116/7 | 1 |
| DB * (175) (Normal/ Elevated) | 44/8 | 114/9 | 0.100 |
Note: *The total available number of patients data.
Abbreviations: HBsAg, hepatitis B surface antigen; MVI, microvascular invasion; BCLC, Barcelona clinic liver cancer staging; AFP, alpha-fetoprotein; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT, gamma-glutamyltransferase; TB, total bilirubin; DB, direct bilirubin.